Select a Month...
Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant
The drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell...
Brotman Baty Institute for Precision Medicine Launches in Seattle
The Brotman Baty Institute for Precision Medicine combines the research strengths and capabilities of UW Medicine, Fred Hutchinson Cancer Research Center and...
Seattle Children’s Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia That Targets CD22 and CD19 Proteins Simultaneously
By launching a bilateral attack on cancer cells, researchers hope to ultimately increase patients’ long-term remission
Seattle Children’s Launches $1 Billion Fundraising Campaign to Transform Children’s Health
It Starts With Yes: The Campaign for Seattle Children’s is the largest in Seattle Children’s 110-year history
Suzanne Beitel Appointed Senior Vice President, Chief Financial Officer of Seattle Children's
Beitel assumes role after serving as executive director in the Public Finance Group at JP Morgan
Dr. Zafar Chaudry Appointed Senior Vice President, Chief Information Officer of Seattle Children's
Chaudry assumes role after serving as chief information officer at Cambridge University Hospitals in the United Kingdom
Seattle Children's Opens CD22 CAR T-Cell Immunotherapy Trial for Children and Young Adults Whose Leukemia Escapes CD19 CAR T-Cell Therapy
Phase 1 trial aims to increase long-term remission, it is the first on the West Coast to target CD22-positive leukemia
Seattle Children’s Brings First-of-its-kind Precision Medicine Clinical Trial to Inflammatory Bowel Disease, Bone Marrow Transplant Patients
Next-generation sequencing to expand diagnostic information available and guide personalized treatment plans
First-In-Human Clinical Trial Aims to Extend Remission for Children and Young Adults With Leukemia Treated With T-Cell Immunotherapy
Phase 1 pilot study utilizes T-cell antigen presenting cells to prolong the persistence of cancer-fighting chimeric antigen receptor (CAR) T cells, reduce the...
Myra Gregorian Appointed Senior Vice President, Chief People Officer of Seattle Children's
Gregorian assumes role after serving as chief human resources officer at Children’s Hospital Los Angeles since 2015